The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments. To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan / F. Pietrantonio, F. Morano, M. Niger, S. Corallo, M. Antista, A. Raimondi, M. Prisciandaro, F. Pagani, N. Prinzi, F. Nichetti, G. Randon, M. Torchio, F. Corti, M. Ambrosini, F. Palermo, M. Palazzo, L. Biamonte, M. Platania, C. Sposito, M. Cosimelli, V. Mazzaferro, S. Pusceddu, C. Cremolini, F. de Braud, M. Di Bartolomeo. - In: CLINICAL COLORECTAL CANCER. - ISSN 1533-0028. - (2020 May 23). [Epub ahead of print] [10.1016/j.clcc.2020.05.004]
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan
F. Pietrantonio
;M. Prisciandaro;G. Randon;F. Corti;M. Ambrosini;C. Sposito;V. Mazzaferro;F. de Braud;
2020
Abstract
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments. To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.File | Dimensione | Formato | |
---|---|---|---|
PIIS1533002820300773.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
309.24 kB
Formato
Adobe PDF
|
309.24 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.